288 related articles for article (PubMed ID: 27256286)
1. A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease.
Hegarty SV; O'Leary E; Solger F; Stanicka J; Sullivan AM; O'Keeffe GW
Neurotox Res; 2016 Oct; 30(3):510-20. PubMed ID: 27256286
[TBL] [Abstract][Full Text] [Related]
2. Activation of p300 histone acetyltransferase by small molecules altering enzyme structure: probed by surface-enhanced Raman spectroscopy.
Mantelingu K; Kishore AH; Balasubramanyam K; Kumar GV; Altaf M; Swamy SN; Selvi R; Das C; Narayana C; Rangappa KS; Kundu TK
J Phys Chem B; 2007 May; 111(17):4527-34. PubMed ID: 17417897
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
4. Investigation of activation mechanism and conformational stability of
Sivanandam M; Manjula S; Kumaradhas P
J Biomol Struct Dyn; 2019 Sep; 37(15):4006-4018. PubMed ID: 30301423
[TBL] [Abstract][Full Text] [Related]
5. Small molecule modulators of histone acetyltransferase p300.
Balasubramanyam K; Swaminathan V; Ranganathan A; Kundu TK
J Biol Chem; 2003 May; 278(21):19134-40. PubMed ID: 12624111
[TBL] [Abstract][Full Text] [Related]
6. Exploring the binding affinities of p300 enzyme activators CTPB and CTB using docking method.
Devipriya B; Parameswari AR; Rajalakshmi G; Palvannan T; Kumaradhas P
Indian J Biochem Biophys; 2010 Dec; 47(6):364-9. PubMed ID: 21355420
[TBL] [Abstract][Full Text] [Related]
7. A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson's disease.
Choong CJ; Sasaki T; Hayakawa H; Yasuda T; Baba K; Hirata Y; Uesato S; Mochizuki H
Neurobiol Aging; 2016 Jan; 37():103-116. PubMed ID: 26545632
[TBL] [Abstract][Full Text] [Related]
8. The Epigenome as a therapeutic target for Parkinson's disease.
Hegarty SV; Sullivan AM; O'Keeffe GW
Neural Regen Res; 2016 Nov; 11(11):1735-1738. PubMed ID: 28123403
[TBL] [Abstract][Full Text] [Related]
9. Curcumin is an inhibitor of p300 histone acetylatransferase.
Marcu MG; Jung YJ; Lee S; Chung EJ; Lee MJ; Trepel J; Neckers L
Med Chem; 2006 Mar; 2(2):169-74. PubMed ID: 16787365
[TBL] [Abstract][Full Text] [Related]
10. NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease.
Anantha J; Goulding SR; Tuboly E; O'Mahony AG; Moloney GM; Lomansey G; McCarthy CM; Collins LM; Sullivan AM; O'Keeffe GW
Mol Neurobiol; 2022 Jan; 59(1):61-76. PubMed ID: 34623600
[TBL] [Abstract][Full Text] [Related]
11. LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's disease.
Mazzocchi M; Goulding SR; Wyatt SL; Collins LM; Sullivan AM; O'Keeffe GW
Mol Cell Neurosci; 2021 Sep; 115():103642. PubMed ID: 34119632
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells.
Wang Y; Wang X; Liu L; Wang X
Neurosci Lett; 2009 Dec; 467(3):212-6. PubMed ID: 19835929
[TBL] [Abstract][Full Text] [Related]
15. Targeting cyclin D3/CDK6 activity for treatment of Parkinson's disease.
Alquézar C; Barrio E; Esteras N; de la Encarnación A; Bartolomé F; Molina JA; Martín-Requero Á
J Neurochem; 2015 Jun; 133(6):886-97. PubMed ID: 25689470
[TBL] [Abstract][Full Text] [Related]
16. β-Ecdysterone Protects SH-SY5Y Cells Against 6-Hydroxydopamine-Induced Apoptosis via Mitochondria-Dependent Mechanism: Involvement of p38(MAPK)-p53 Signaling Pathway.
Pan Z; Niu Y; Liang Y; Zhang X; Dong M
Neurotox Res; 2016 Oct; 30(3):453-66. PubMed ID: 27229883
[TBL] [Abstract][Full Text] [Related]
17. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
[TBL] [Abstract][Full Text] [Related]
18. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
Ganai SA; Banday S; Farooq Z; Altaf M
Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
[TBL] [Abstract][Full Text] [Related]
19. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
